A. Oliver Sartor, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Invitae
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Advancel Accelerator Applications (AAA)
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Endocyte
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    EMD Serono
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Dendreon
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Myovant
    Date added:
    Date updated:
    09/19/2022

Pages

Return to Webinar: Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment (2020)